CFO and director changes, weak Q3 results at Anlon Healthcare

Cfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹12.68

prior close

₹12.87

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-3.4% vs market

Pharmaceuticals peers, median of 159sector+0.4%-2.9% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.7

15m

-1.7

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4+1.0-3.4+0.4-2.9

Next day

-3.0+0.5-3.5+0.3-3.3

-3.9-0.0-3.9+0.0-3.9

-4.6-1.5-3.1-1.2-3.4

-4.8-2.2-2.6-1.7-3.1

-3.9-1.2-2.7-1.8-2.2

-7.7-2.4-5.4-2.5-5.2

15d

-14.0-8.8-5.2-6.9-7.1

-1.1-8.3+7.2-5.1+4.0

+2.2-3.5+5.8-3.5+5.7

+12.0+6.4+5.6+2.8+9.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anlon Healthcare's board approved CFO Hitesh Makwana's resignation citing pre-occupation and appointed Naimish Bhatt as new CFO. Independent Director Shailesh Thakkar also resigned citing health issues, with Kishan Raja appointed as new ID. Q3 FY26 revenue fell to about Rs 35.58 crore from Rs 71.36 crore year-on-year, with a loss of Rs 2.49 crore against a profit of Rs 10.61 crore last year. Nine month FY26 profit stood at Rs 18.02 crore.

Likely market impact

Sharp Q3 revenue drop and swing to loss may pressure the stock. Multiple leadership changes add near-term uncertainty for shareholders.